IOVA

Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET

Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

Should You Buy This Cathie Wood Biotech Stock?

Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting

Iovance: Down And Rebound